Deutsche Bank Downgrades Novo Nordisk to Sell After 70% Stock Crash
· Business · MarketWatch, Wall Street Journal
Deutsche Bank has downgraded Novo Nordisk, the maker of Ozempic, to a sell rating after the stock plunged roughly 70% from its peak. The move marks a rare bearish call from Wall Street on the Danish pharma giant, which has been a market darling on the back of demand for its GLP-1 obesity and diabetes drugs. Analysts had previously been reluctant to recommend selling despite signs of slowing growth and mounting competition. The downgrade signals growing concern that the GLP-1 boom may be plateauing.
Why it matters
The downgrade shakes confidence in one of Europe's most valuable companies and signals to investors that the GLP-1 drug frenzy driving obesity-treatment stocks may be losing momentum, with ripple effects across the pharma and biotech sector.
Read the original report — MarketWatch
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.